hepaCAM和VEGF基因表达与肾透明细胞癌侵袭转移关系的探讨

hepaCAM and VEGF Gene Expression in Renal Cell Carcinoma and Their Relations to Tumor Metastasis and Tumor Invasion

研究肾癌细胞株786-0,RC-2及肾透明细胞癌组织中肝细胞黏附分子(hepatocyte cell adhesion molecule,hepaC-AM)和血管内皮生长因子(VEGF)mRNA表达及其与肾透明细胞癌侵袭转移的关系。应用逆转录聚合酶链反应(RT-PCR)检测786-0、RC-2、正常肾组织hepaCAM和VEGFmRNA表达,73例肾透明细胞癌组织及相应癌旁组织中hepaCAMmRNA表达,43例肾透明细胞癌组织及相应癌旁组织VEGFmRNA表达,并比较它们之间的差异性和相关性。与正常肾组织比较786-0,RC-2的hepaCAMmRNA显著降低(P<0.05);VEGFmRNA显著升高(P<0.05)。肾透明细胞癌组织hepaCAMmRNA显著低于癌旁组织(P<0.05);VEGFmRNA显著高于癌旁组织(P<0.05)。在肾透明细胞癌组织中临床Ⅰ+Ⅱ期和Ⅲ+Ⅳ期两组VEGFmRNA表达差异具有统计学意义(P<0.05),hepaCAM与VEGFmRNA呈负相关(r=-0.329,P<0.05)。提示hepaC-AM基因缺失可能参与肾透明细胞癌侵袭转移,其机制可能与调节VFGF表达改变有关,hepaCAM有望成为一种新的肾癌基因治疗的靶分子。

It was to investigate the expression of hepaCAM and VEGF mRNA in renal cancer cells 786-0,RC-2 ,renal cell carcinomas（RCC）and their relation to invasion and metastasis of renal cell carcinomas（RCC）. The expression of hepaC, AM and VEGF mRNA was determined in 786-0,RC-2,normal renal tissue,the expression of hepaCAM mRNA was determined in 73 cases of RCC and corresponding peripheral noncancerous tissue and the expression of VEGF mRNA was determined in 43 cases of RCC and corresponding peripheral noncancerous tissue by reverse transcription polymerase chain reaction（RT-PCR）. The difference and eorelation be- tween each group were compared and analyzed. Results indicate that hepaCAM mRNA＇s expression was lower in 786-0, RC-2 than in the normal tissue （ P 〈 0. 05 ） , VEGF mRNA＇s expression was higher in 786-0, RC-2 than that of in the normal tissue （ P 〈 0.05 ）. In RCC tissues hepaCAM mRNA＇s expression was significantly lower than corresponding peripheral noncancerous tissues （ P 〈 0.05 ）, VEGF mRNA＇s expression was significantly higher than corresponding peripheral noncancerous tissues. There are significance between stage Ⅰ ＋ Ⅱ group and stage Ⅲ ＋ Ⅳ group as far as VEGF mRNA expression are concerned （P 〈 0. 05 ）and hepaCAM mRNA expression level was negatively correlated with the VEGF mRNA in RCC （ r = - 0. 329,P 〈 0. 05 ）. Therefore, the down regulation of hepaCAM contributes to the invasiveness and metastasis of RCC,and the mechanism may be associated with the change of VEGF expression. hepaCAM is expected to become a new molecular in the gene therapy of RCC.